skip to content
Dovepress - Open Access to Scientific and Medical Research
View our mobile site

8129

Aspirin and clopidogrel hyporesponsiveness and nonresponsiveness in patients with coronary artery stenting

Review

(3522) Views  (1196) Full article downloads

Authors: Rakesh K Sharma, Hanumanth K Reddy, Vibhuti N Singh, et al

Published Date November 2009 Volume 2009:5 Pages 965 - 972
DOI: http://dx.doi.org/10.2147/VHRM.S6787

Rakesh K Sharma1, Hanumanth K Reddy1, Vibhuti N Singh2, Rohit Sharma1, Donald J Voelker1, Girish Bhatt1

1Medical Center of South Arkansas, El Dorado, University of Arkansas for Medical Sciences, Little Rock, AR, USA; 2Bayfront Medical Center, St. Petersburg, University of South Florida, Tampa, FL, USA

Abstract: Patients undergoing coronary artery stenting receive an antiplatelet regimen to reduce the risk of antithrombotic complications. Current guidelines recommend the use of acetyl salicylic acid (aspirin) and clopidogrel as evidenced by large clinical trials. There has been a concern about variable responses of patients to aspirin and clopidogrel which may predispose them to subacute stent thrombosis or late stent thrombosis. Up to 25% of patients with acute myocardial infarction (AMI) undergoing percutaneous coronary intervention (PCI) were found to have hyporesponsiveness or resistance to clopidogrel which may predispose them to recurrent events. Dual antiplatelet regimen is a standard therapy in these patients and there is always a concern about variable responses to aspirin and clopidogrel predisposing them to acute coronary syndrome (ACS). Prevalence of this hyporesponsiveness or resistance may be due to noncompliance, genetic mutations, co-morbid situations and concomitant use of other drugs. This issue is of considerable importance in the era of coronary drug eluting stents when a long-term dual antiplatelet regimen is needed. This paper is a review for clinicians taking care of such patients with hyporesponsiveness or nonresponsiveness to dual antiplatelet regimen.

Keywords: aspirin, clopidogrel, acute coronary syndrome, coronary artery stenting






 

Other articles by Dr Rakesh Sharma

Cardiac risk stratification: Role of the coronary calcium score
Coronary computed tomographic angiography (CCTA) in community hospitals: “current and emerging role”
Evolving role of platelet function testing in coronary artery interventions
The interaction between clopidogrel and proton pump inhibitors (PPI): is there any clinical relevance?
Thinking beyond low-density lipoprotein cholesterol: strategies to further reduce cardiovascular risk
  • Join ISVH

    Be part of the World's leading experts in vascular health by joining the International Society of Vascular Health (ISVH)

  • Testimonials

    "... I was impressed at the rapidity of publication from submission to final acceptance." Dr Edwin Thrower, PhD, Yale University